The EU may grant prior approval for the use of the remixer in the following days

11 months ago

The head of the European Medicines Agency (EMA), Guido Rassy, said that a preliminary authorization for the use of the American Gilead’s remedesivir drug in the treatment of patients with COVID-19 may be issued in the coming days, reports Reuters.

“Perhaps a conditional market authorization will be issued in the coming days,” Racy said at a hearing at the European Parliament in Brussels.

The EMA has already recommended the use of remixivir in exceptional circumstances, allowing patients to prescribe the drug before final approval is granted.

Leave a Comment